IL1B and familial Mediterranean fever: For patients who are colchicine-resistant or intolerant (5%-10% of cases), biologic therapies targeting IL-1β, such as anakinra, canakinumab, or rilonacept, have proven effective in reducing attacks and systemic inflammation [2,5]. The phase 3 CLUSTER (Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes) trial demonstrated the safety and sustained efficacy of canakinumab in colchicine-resistant FMF, supporting its role as a second-line therapy [5].